Global Pediatric Growth Hormone Market 2025 by Company, Regions, Type and Application, Forecast to 2031
Description
According to our (Global Info Research) latest study, the global Pediatric Growth Hormone market size was valued at US$ 3727 million in 2024 and is forecast to a readjusted size of USD 5251 million by 2031 with a CAGR of 5.1% during review period.
Growth hormones deficiency is a rare condition but it mainly affects the children. The recombinant form of a growth hormone called somatotropin is generally prescribed to treat pediatric patients with growth hormone deficiency. Somatotropin or growth hormone injections are prescribed for pediatric patients with turner syndrome, short stature, Prader-Willi syndrome, Noonan syndrome and other disorders.
The global pediatric growth hormone market refers to the market for medications and therapies used to treat growth hormone deficiency (GHD) and related disorders in children. Growth hormone is an important hormone produced by the pituitary gland that plays a crucial role in regulating growth, development, and metabolism.
Pediatric growth hormone deficiency can occur due to various factors, including genetic conditions, congenital anomalies, brain injuries, and certain medical treatments. Treatment with growth hormone therapy aims to stimulate growth and development in children who have insufficient or inadequate production of growth hormone.
The global market for pediatric growth hormone is primarily driven by factors such as the increasing prevalence of growth hormone deficiency, rising awareness about the benefits of growth hormone therapy, advances in treatment options, and improving healthcare infrastructure.
Growth hormone therapy for children with growth hormone deficiency involves the subcutaneous administration of synthetic growth hormone on a daily basis. The therapy is typically initiated during childhood and continued until the patient reaches adult height or the maximum growth potential is achieved.
Geographically, North America and Europe hold a significant share in the global pediatric growth hormone market due to the well-established healthcare systems, high awareness levels, and the presence of key market players. The Asia Pacific region is also expected to witness significant growth due to the increasing prevalence of growth hormone deficiency and improving healthcare infrastructure.
Key pharmaceutical companies involved in the production and distribution of pediatric growth hormone products include Novo Nordisk, Pfizer, Eli Lilly and Company, Merck & Co., and Ferring Pharmaceuticals, among others. These companies are focused on developing advanced growth hormone formulations, conducting clinical trials, and expanding their product portfolios to address the specific needs of pediatric patients.
It’s important to note that the pediatric growth hormone market is regulated, and treatment decisions are made based on the diagnosis and guidance of healthcare professionals specializing in pediatric endocrinology. Proper assessment, diagnosis, and monitoring of the child’s growth and hormone levels are essential for safe and effective treatment.
In summary, the global pediatric growth hormone market is driven by factors such as the increasing prevalence of growth hormone deficiency, advances in treatment options, and improving healthcare infrastructure. The market is expected to witness steady growth as awareness about growth hormone therapy increases and healthcare providers continue to diagnose and treat pediatric patients with growth hormone deficiency.
This report is a detailed and comprehensive analysis for global Pediatric Growth Hormone market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Pediatric Growth Hormone market size and forecasts, in consumption value ($ Million), 2020-2031
Global Pediatric Growth Hormone market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Pediatric Growth Hormone market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Pediatric Growth Hormone market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Pediatric Growth Hormone
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Pediatric Growth Hormone market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck KGaA, Novo Nordisk A/S, Ferring B.V, Genentech, Inc., Pfizer Inc., Eli Lilly & Company, Novartis AG, BioPartners GmbH, Ipsen Biopharmaceuticals, Teva Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Pediatric Growth Hormone market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Growth Hormone Deficiency
Turner Syndrome
Prader-Willi Syndrome
Noonan Syndrome
Others
Market segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Market segment by players, this report covers
Merck KGaA
Novo Nordisk A/S
Ferring B.V
Genentech, Inc.
Pfizer Inc.
Eli Lilly & Company
Novartis AG
BioPartners GmbH
Ipsen Biopharmaceuticals
Teva Pharmaceuticals
Anhui Anke Biotechnology (Group) Co., Ltd.
LG Chem
GeneScience Pharmaceuticals Co., Ltd.
Ascendis Pharma A/S
Changchun High & New Tech Industry Inc
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Pediatric Growth Hormone product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Pediatric Growth Hormone, with revenue, gross margin, and global market share of Pediatric Growth Hormone from 2020 to 2025.
Chapter 3, the Pediatric Growth Hormone competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Pediatric Growth Hormone market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Pediatric Growth Hormone.
Chapter 13, to describe Pediatric Growth Hormone research findings and conclusion.
Growth hormones deficiency is a rare condition but it mainly affects the children. The recombinant form of a growth hormone called somatotropin is generally prescribed to treat pediatric patients with growth hormone deficiency. Somatotropin or growth hormone injections are prescribed for pediatric patients with turner syndrome, short stature, Prader-Willi syndrome, Noonan syndrome and other disorders.
The global pediatric growth hormone market refers to the market for medications and therapies used to treat growth hormone deficiency (GHD) and related disorders in children. Growth hormone is an important hormone produced by the pituitary gland that plays a crucial role in regulating growth, development, and metabolism.
Pediatric growth hormone deficiency can occur due to various factors, including genetic conditions, congenital anomalies, brain injuries, and certain medical treatments. Treatment with growth hormone therapy aims to stimulate growth and development in children who have insufficient or inadequate production of growth hormone.
The global market for pediatric growth hormone is primarily driven by factors such as the increasing prevalence of growth hormone deficiency, rising awareness about the benefits of growth hormone therapy, advances in treatment options, and improving healthcare infrastructure.
Growth hormone therapy for children with growth hormone deficiency involves the subcutaneous administration of synthetic growth hormone on a daily basis. The therapy is typically initiated during childhood and continued until the patient reaches adult height or the maximum growth potential is achieved.
Geographically, North America and Europe hold a significant share in the global pediatric growth hormone market due to the well-established healthcare systems, high awareness levels, and the presence of key market players. The Asia Pacific region is also expected to witness significant growth due to the increasing prevalence of growth hormone deficiency and improving healthcare infrastructure.
Key pharmaceutical companies involved in the production and distribution of pediatric growth hormone products include Novo Nordisk, Pfizer, Eli Lilly and Company, Merck & Co., and Ferring Pharmaceuticals, among others. These companies are focused on developing advanced growth hormone formulations, conducting clinical trials, and expanding their product portfolios to address the specific needs of pediatric patients.
It’s important to note that the pediatric growth hormone market is regulated, and treatment decisions are made based on the diagnosis and guidance of healthcare professionals specializing in pediatric endocrinology. Proper assessment, diagnosis, and monitoring of the child’s growth and hormone levels are essential for safe and effective treatment.
In summary, the global pediatric growth hormone market is driven by factors such as the increasing prevalence of growth hormone deficiency, advances in treatment options, and improving healthcare infrastructure. The market is expected to witness steady growth as awareness about growth hormone therapy increases and healthcare providers continue to diagnose and treat pediatric patients with growth hormone deficiency.
This report is a detailed and comprehensive analysis for global Pediatric Growth Hormone market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Pediatric Growth Hormone market size and forecasts, in consumption value ($ Million), 2020-2031
Global Pediatric Growth Hormone market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Pediatric Growth Hormone market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Pediatric Growth Hormone market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Pediatric Growth Hormone
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Pediatric Growth Hormone market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck KGaA, Novo Nordisk A/S, Ferring B.V, Genentech, Inc., Pfizer Inc., Eli Lilly & Company, Novartis AG, BioPartners GmbH, Ipsen Biopharmaceuticals, Teva Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Pediatric Growth Hormone market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Growth Hormone Deficiency
Turner Syndrome
Prader-Willi Syndrome
Noonan Syndrome
Others
Market segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Market segment by players, this report covers
Merck KGaA
Novo Nordisk A/S
Ferring B.V
Genentech, Inc.
Pfizer Inc.
Eli Lilly & Company
Novartis AG
BioPartners GmbH
Ipsen Biopharmaceuticals
Teva Pharmaceuticals
Anhui Anke Biotechnology (Group) Co., Ltd.
LG Chem
GeneScience Pharmaceuticals Co., Ltd.
Ascendis Pharma A/S
Changchun High & New Tech Industry Inc
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Pediatric Growth Hormone product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Pediatric Growth Hormone, with revenue, gross margin, and global market share of Pediatric Growth Hormone from 2020 to 2025.
Chapter 3, the Pediatric Growth Hormone competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Pediatric Growth Hormone market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Pediatric Growth Hormone.
Chapter 13, to describe Pediatric Growth Hormone research findings and conclusion.
Table of Contents
106 Pages
- 1 Market Overview
- 2 Company Profiles
- 3 Market Competition, by Players
- 4 Market Size Segment by Type
- 5 Market Size Segment by Application
- 6 North America
- 7 Europe
- 8 Asia-Pacific
- 9 South America
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
